Drug Approval | June 01, 2022
FDA approves Roche’s Evrysdi for use in babies under two months with SMA
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
The study was conducted in equal laboratory conditions in the Spallanzani Institute in Italy on comparable sera samples from individuals vaccinated with Sputnik V and Pfizer with a similar level of IgG antibodies and virus-neutralizing activity (VNA) against Wuhan variant.
Successfully removed peanut from the child’s left lung through bronchoscopy
Dr Rupali Paranjape, an experienced regulatory and compliance consultant and author of Blue Ocean of Compliance shares insights on her book in an interview with Thomas C Thottathil, Editor, www.indianpharmapost.com
Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to substantial burden and often disability among patients
Includes thermostabilized Ebola vaccines
Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series
Quantib Prostate is an AI-based software solution that advances the MRI prostate reporting workflow and is accessible directly from the radiologist's reading station
Subscribe To Our Newsletter & Stay Updated
